CAD-1005 moves toward Phase 3 as FDA backs thrombotic endpoint strategy in heparin-induced thrombocytopenia
Cadrenal Therapeutics gains FDA alignment on a Phase 3 CAD-1005 trial in HIT after encouraging thrombosis data. See the risks and next steps.
Pharma & Biotech